Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Evaluation of self-collected vaginal specimens for the detection of high-risk HPV infection and the prediction of high-grade cervical intraepithelial lesions in a high-burden, low-resource setting.

Toliman PJ, Kaldor JM, Badman SG, Phillips S, Tan G, Brotherton JML, Saville M, Vallely AJ, Tabrizi SN.

Clin Microbiol Infect. 2018 Jun 12. pii: S1198-743X(18)30471-3. doi: 10.1016/j.cmi.2018.05.025. [Epub ahead of print]

PMID:
29906593
2.

Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012).

Diaz A, Baade PD, Valery PC, Whop LJ, Moore SP, Cunningham J, Garvey G, Brotherton JML, O'Connell DL, Canfell K, Sarfati D, Roder D, Buckley E, Condon JR.

PLoS One. 2018 May 8;13(5):e0196764. doi: 10.1371/journal.pone.0196764. eCollection 2018.

3.

Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.

Garland SM, Cornall AM, Brotherton JML, Wark JD, Malloy MJ, Tabrizi SN; VACCINE study group.

Vaccine. 2018 May 31;36(23):3221-3230. doi: 10.1016/j.vaccine.2018.04.080. Epub 2018 Apr 30.

PMID:
29724506
4.

Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination.

Machalek DA, Garland SM, Brotherton JML, Bateson D, McNamee K, Stewart M, Rachel Skinner S, Liu B, Cornall AM, Kaldor JM, Tabrizi SN.

J Infect Dis. 2018 Apr 23;217(10):1590-1600. doi: 10.1093/infdis/jiy075.

PMID:
29425358
5.

Reply to San Giorgi and Dikkers.

Novakovic D, Brotherton JML.

J Infect Dis. 2018 Apr 11;217(9):1504-1505. doi: 10.1093/infdis/jix675. No abstract available.

PMID:
29293995
6.

HPV vaccination of immunocompromised hosts.

Garland SM, Brotherton JML, Moscicki AB, Kaufmann AM, Stanley M, Bhatla N, Sankaranarayanan R, de Sanjosé S, Palefsky JM; IPVS.

Papillomavirus Res. 2017 Dec;4:35-38. doi: 10.1016/j.pvr.2017.06.002. Epub 2017 Jun 3.

7.

A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program.

Novakovic D, Cheng ATL, Zurynski Y, Booy R, Walker PJ, Berkowitz R, Harrison H, Black R, Perry C, Vijayasekaran S, Wabnitz D, Burns H, Tabrizi SN, Garland SM, Elliott E, Brotherton JML.

J Infect Dis. 2018 Jan 4;217(2):208-212. doi: 10.1093/infdis/jix498.

PMID:
29136168
8.

Not all HPV nucleic acid tests are equal: only those calibrated to detect high grade lesions matter for cervical screening.

Hawkes D, Brotherton JML, Saville M.

Clin Microbiol Infect. 2018 Apr;24(4):436-437. doi: 10.1016/j.cmi.2017.10.023. Epub 2017 Dec 6. No abstract available.

PMID:
29104173
9.

Monitoring the impact of HPV vaccine in males-Considerations and challenges.

Brotherton JML, Giuliano AR, Markowitz LE, Dunne EF, Ogilvie GS.

Papillomavirus Res. 2016 Dec;2:106-111. doi: 10.1016/j.pvr.2016.05.001. Epub 2016 May 17.

10.

Early sexual experiences of teenage heterosexual males in Australia: a cross-sectional survey.

Chow EPF, Wigan R, McNulty A, Bell C, Johnson M, Marshall L, Regan DG, Owen L, Brotherton JML, Bradshaw CS, Fairley CK, Russell D, Chen MY; IMPRESS Study Group.

BMJ Open. 2017 Oct 15;7(10):e016779. doi: 10.1136/bmjopen-2017-016779.

11.

Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance.

Pillsbury AJ, Quinn HE, Evans TD, McIntyre PB, Brotherton JML.

Clin Infect Dis. 2017 Sep 1;65(5):827-832. doi: 10.1093/cid/cix436.

PMID:
29017279
12.

Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage.

Brotherton JML, Bloem PN.

Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:42-58. doi: 10.1016/j.bpobgyn.2017.08.010. Epub 2017 Sep 6. Review.

PMID:
28986092
13.

The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation.

Drolet M, Laprise JF, Brotherton JML, Donovan B, Fairley CK, Ali H, Bénard É, Martin D, Brisson M.

J Infect Dis. 2017 Dec 5;216(10):1205-1209. doi: 10.1093/infdis/jix476.

PMID:
28968800
14.

Confirming cross-protection of bivalent HPV vaccine.

Brotherton JML.

Lancet Infect Dis. 2017 Dec;17(12):1227-1228. doi: 10.1016/S1473-3099(17)30539-X. Epub 2017 Sep 28. No abstract available.

PMID:
28965956
15.

Progress in HPV vaccination in low- and lower-middle-income countries.

LaMontagne DS, Bloem PJN, Brotherton JML, Gallagher KE, Badiane O, Ndiaye C.

Int J Gynaecol Obstet. 2017 Jul;138 Suppl 1:7-14. doi: 10.1002/ijgo.12186.

PMID:
28691329
16.

Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.

Brotherton JML, Tabrizi SN, Phillips S, Pyman J, Cornall AM, Lambie N, Anderson L, Cummings M, Payton D, Scurry JP, Newman M, Sharma R, Saville M, Garland SM.

Int J Cancer. 2017 Oct 15;141(8):1576-1584. doi: 10.1002/ijc.30871. Epub 2017 Jul 14.

PMID:
28677147
17.

Opportunities to increase rates of human papillomavirus vaccination in the New South Wales school program through enhanced catch-up.

Staples C, Butler M, Nguyen J, Durrheim DN, Cashman P, Brotherton JML.

Sex Health. 2016 Nov;13(6):536-539. doi: 10.1071/SH15132.

PMID:
27568237

Supplemental Content

Loading ...
Support Center